GlobeNewswire·May 14, 2026, 4:20 PM ET

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

SER

Serina Therapeutics initiated its Phase 1b registrational clinical study for SER-252 in advanced Parkinson's disease, with the first patient dosed in February 2026.
The company targets completion of Cohort 1 enrollment & dosing by the end of Q3 2026 & TFL data availability from the single-ascending-dose arm in the first half of 2027.
Serina closed a private placement financing round in March & April 2026, generating $21.2 million in gross proceeds to support SER-252 advancement.
The financing satisfied requirements for the automatic conversion of Series A Preferred Stock into common stock & amended the Senior Unsecured Convertible Promissory Note to remove further borrowing obligations.
First quarter 2026 operating expenses totaled $6.3 million, an increase from $5.9 million in the same period of 2025, driven by R&D & general administrative costs.
Net loss for the three months ended March 31, 2026, was $6.9 million, or $0.58 per share, compared to a net loss of $4.8 million, or $0.49 per share, in 2025.
Cash & cash equivalents reached $24.5 million as of March 31, 2026, including $5.2 million received in April 2026 from the financing.
The Phase 1b study is a randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, & pharmacokinetics of subcutaneous SER-252 across sites in the U.S. & Australia.
SER-252 utilizes Serina's proprietary POZ Platform to optimize apomorphine for continuous dopaminergic stimulation without skin reactions.
Serina maintains a strategic partnership with Pfizer, Inc. for a non-exclusive license to use its POZ polymer technology in lipid nanoparticle drug delivery formulations.